abiraterone, zytiga, prostate, prostate cancer, prostate cancer medicine,Zytiga, abiraterone, prostate cancer, metastatic, castration-resistant, testosterone

Zytiga

Read more

ZYTIGA® (abiraterone acetate) is a prescription medicine that is used along with prednisone. ZYTIGA® is used to treat men with castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has spread to other parts of the body.

Product Description

Zytiga (abiraterone) is indicated for use in combination with prednisolone to treat metastatic castration-resistant prostate cancer that has progressed during or after docetaxel treatment.

PHARMACOLOGY

By inhibiting CYP17 (17alpha-hydroxylase/C17,20-lyase), abiraterone blocks the synthesis of testosterone in the adrenal glands and testes, as well as in the prostate tumour itself.1

CLINICAL STUDIES

Approval of abiraterone was based on a randomised, double-blind phase 3 trial in 1195 men with metastatic prostate cancer who had previously received docetaxel. In this trial, men who were given abiraterone 1g daily, plus low-dose prednisone or prednisolone, lived for a median of 14.8 months compared with 10.9 months for men taking placebo plus prednisolone or prednisone.1 This difference translated into a 35.4% reduction in the risk of death with abiraterone compared with placebo (95% CI 23–46%; p<0.001).2

The proportion of patients who experienced a 30% reduction in the worst pain intensity was also significantly greater with abiraterone than placebo (44% vs 27%; p=0.0002).

Reviews

There are no reviews yet.

Be the first to review “Zytiga”

Your email address will not be published. Required fields are marked *